KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Depreciation & Amortization (CF) (2016 - 2025)

AbbVie (ABBV) has disclosed Depreciation & Amortization (CF) for 14 consecutive years, with $203.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 1.46% to $203.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $762.0 million, a 0.26% change, with the full-year FY2025 number at $762.0 million, changed 0.26% from a year prior.
  • Depreciation & Amortization (CF) was $203.0 million for Q4 2025 at AbbVie, up from $192.0 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $223.0 million in Q3 2021 to a low of $173.0 million in Q4 2021.
  • A 5-year average of $193.0 million and a median of $191.5 million in 2024 define the central range for Depreciation & Amortization (CF).
  • Biggest YoY gain for Depreciation & Amortization (CF) was 79.13% in 2021; the steepest drop was 23.79% in 2021.
  • AbbVie's Depreciation & Amortization (CF) stood at $173.0 million in 2021, then increased by 13.29% to $196.0 million in 2022, then decreased by 4.59% to $187.0 million in 2023, then increased by 10.16% to $206.0 million in 2024, then decreased by 1.46% to $203.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Depreciation & Amortization (CF) are $203.0 million (Q4 2025), $192.0 million (Q3 2025), and $186.0 million (Q2 2025).